<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3071">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811456</url>
  </required_header>
  <id_info>
    <org_study_id>MOIS-CoR</org_study_id>
    <nct_id>NCT04811456</nct_id>
  </id_info>
  <brief_title>MultiOrgan Inflammatory Syndromes COVID-19 Related Study</brief_title>
  <acronym>MOIS-CoR</acronym>
  <official_title>MultiOrgan Inflammatory Syndromes COVID-19 Related Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wrocław Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study comprise a nationwide, voluntary, on-line survey of inflammatory syndromes in&#xD;
      children for retrospective (since 4th March 2020) and prospective data collection. Our aim&#xD;
      was to capture and describe multisystem inflammatory syndrome in children (MIS-C) in Poland.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The voluntary surveillance for retrospective (since 4th March) and prospective data&#xD;
      collection was initiated under the National Consultant of Pediatrics auspices. Anonymized&#xD;
      patient data from pediatric hospitals from all over the country are extracted from electronic&#xD;
      and paper records and collected through online form developed for that purpose. Before the&#xD;
      surveillance was launched, reporting clinicians underwent an online training, which included&#xD;
      the current state of knowledge about multisystem inflammatory syndrome in children (MIS-C).&#xD;
      Patient management is at the discretion of the relevant treating clinicians.&#xD;
&#xD;
      KD and aKD were defined following the American Heart Association (AHA) guidelines.&#xD;
&#xD;
      TSS was established based on modified criteria by the Centers for Disease Control and&#xD;
      Prevention.&#xD;
&#xD;
      MAS was diagnosed based on the Paediatric Rheumatology International Trials Organization&#xD;
      (PRINTO) criteria for MAS classification.&#xD;
&#xD;
      The definition of the inflammatory syndrome was based on the WHO MIS-C definition with the&#xD;
      exclusion of SARS-CoV-2 confirmation.&#xD;
&#xD;
      For patients who met the inclusion criteria, demographic data, past medical history, data on&#xD;
      COVID-19 exposure, clinical symptoms, physical examination findings, laboratory, imaging, and&#xD;
      cardiologic tests results, treatment, and outcome data are collected.&#xD;
&#xD;
      All study definitions are defined in accordance to relevant guidelines and evaluated&#xD;
      automatically with the use of a dedicated software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">August 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>PICU</measure>
    <time_frame>5 years</time_frame>
    <description>pediatric intensive care unit treatment need</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart dysfunction</measure>
    <time_frame>5 years</time_frame>
    <description>Heart dysfunction is defined as ejection fraction (EF) of &lt;55% and severe heart dysfunction as EF &lt;35%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAA</measure>
    <time_frame>5 years</time_frame>
    <description>Coronary artery abnormalities comprise both coronary dilation and/or coronary aneurysm. Dilation was defined by Z-score between 2 to 2.5, while aneurysm by Z score ≥2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>5 years</time_frame>
    <description>Hypotension is defined by a minimal systolic blood pressure (sBP) below 70+2×age (in years) mmHg or below 90 mmHg for children &gt;10 years old</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MIS-C</arm_group_label>
    <description>Cases fulfilling following criteria:&#xD;
fever ≥3 days&#xD;
at least two of the following:&#xD;
rash or bilateral conjunctivitis or mucocutaneous inflammation signs&#xD;
hypotension&#xD;
features of myocardial dysfunction, pericarditis, or coronary artery abnormality, based on echocardiographic findings or elevated B-type natriuretic peptide (BNP)/N-terminal-pro-BNP (NT-proBNP) or troponin&#xD;
evidence of coagulopathy&#xD;
acute gastrointestinal problems&#xD;
elevated inflammatory markers AND&#xD;
no other apparent microbial cause&#xD;
evidence of COVID-19 (positive real-time polymerase chain reaction, antigen test or serology), or personal history of COVID-19 or contact with a proven COVID-19 case</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>multisystem inflammatory syndrome in children (MIS-C)</intervention_name>
    <description>as in group description</description>
    <arm_group_label>MIS-C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children aged 0-18 years old hospitalized with inflammatory conditions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who required hospitalization since 4th March 2020;&#xD;
&#xD;
          -  diagnosed Kawasaki disease (KD) or incomplete (atypical) Kawasaki disease (aKD) or&#xD;
             toxic shock syndrome (TSS) or macrophage activation syndrome (MAS) or unspecified&#xD;
             inflammatory syndrome;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other infectious and non-infectious causes that could be responsible for the disease&#xD;
&#xD;
        SARS-CoV-2 polymerase chain reaction (PCR) or serology result could have been positive or&#xD;
        negative. Due to limited availability and reliability of serologic testing, proven or&#xD;
        likely COVID-19 criterion was not a condition determining inclusion to the registry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Okarska-Napierała</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdalena Okarska-Napierała, PhD</last_name>
    <phone>+48503065849</phone>
    <email>magda.okarska@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Dudek, MD</last_name>
    <email>natalia.dudek@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Warsaw Children's Hospital</name>
      <address>
        <city>Warsaw</city>
        <zip>02091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Okarska-Napierala, MD</last_name>
      <phone>+48 503 065 849</phone>
      <email>mnapierala@wum.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University</name>
      <address>
        <city>Wrocław</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamila Ludwikowska</last_name>
      <email>kama.ludwikowska@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MIS-C</keyword>
  <keyword>PIMS-TS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>hyperinflammation</keyword>
  <keyword>children</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

